
Cardiology
Latest News
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Michelle O’Donoghue, MD, discusses the results of Part A of the TYDAL-TIMI 78 trial, demonstrating MAR001’s comparative efficacy to placebo.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Robert Rosenson, MD, discusses the long-term extension of the phase 3 PALISADE trial, which demonstrated plozasiran’s association with lower ApoC3 and fasting TG.

Sachdev explains how VasCog-2-WSO criteria integrate new MRI markers, biomarkers, and unified terminology for vascular dementia.

Behnood Bikdeli, MD, MS, discusses his long-term follow-up to the HI-PRO study, which noted apixaban’s lasting effects on venous thromboembolism.

Ryan Tedford, MD, discusses his analysis of the phase 2 CADENCE trial, highlighting sotatercept’s beneficial effects on both the right and left sides of the heart.

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

Todd Villines, MD, discusses the PARAMOUNT trial, which contrasted AI-based CT scan analysis against standard-of-care in patients with suspected CAD.

Gregory Piazza, MD, MS, discusses the results of ROXI-CATH, which illustrated amrecibart’s and cenvacibart’s efficacy in reducing thrombosis events without increasing bleeding.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.


































































